Tweet

Biotech2k

21 Nov, 9 tweets, 2 min read

Looking at my Genomics Companies:

This has probably been the most bubbly space in biotech the past year. I dumped all these companies back in late January and only recently started buying any of them back.

I love the genomics space, but the cart is way ahead of the horse at this point. I think many of them are now down 50% or more from their highs as human behavior always goes from bubble to bust and back again. I still don't think any of these scream cheap yet.

I have:

$BEAM 2.02%
$CRSP .69%
$PACB 1.38%
$NVTA 1.38%

This theme makes up 5.47% of my portfolio.

$BEAM is probably the fan favorite, but its the only CRISPR company without a single piece of human clinical data. That makes it the highest risk bet and more could go wrong with this tech then the original. Hopes and Dreams is not an investment strategy so waiting on real data.

$CRSP isn't my favorite after I sold it all in January. They are the most advanced and have the most reasonable value which means I will take that bet. They still have the same tech as those more bubbly names. That means its too early to declare anyone a winner.

$PACB is my sequencing company for long and short reads. They were the only company that stood out for me on the tech and management. It doesn't hurt that they go well with my next pick in $NVTA.

$NVTA uses the $PACB sequencers to offer all kinds of genetics testing across all applications form genetic disease diagnosis to cancer. They are building the platform to translate genetic information into a diagnostic and treatment application to improve outcomes.

Most of these position I just recently started buying back. Some of them are new like $PACB and $NVTA, but I at least waited for them to crash before I started buying. I could easily cut this space to 3 names by selling $CRSP which is my least conviction.

Matter of fact, I wouldn't mind owning no CRISPR companies as they are still massively bubbly on hype and valuations. They could lose another 50% to get inline with the rest of these genomics names that are only $3 to $5 billion market caps.

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @Biotech2k1

Biotech2k

@Biotech2k1

20 Nov

Looking at my Synthetic Biology Companies:

The synthetic biology space is all about creating new biology. This is mostly around engineering yeast or bacteria to become tiny factories. This offers a sustainable resource for rare products.

I have:

$DNA 1.38%
$TWST 1.38%
$ARMS 2.06%
$CDXS .69%

This theme makes up 5.51% of my portfolio.

$DNA is the fan favorite for this space, but it also prices in a huge amount of success already. They focus on engineering microbes to be tiny factories to product products. They also engineer microbes for commercial products like probiotics.

Read 9 tweets

Biotech2k

@Biotech2k1

19 Nov

I snagged back a starter position in $CRSP today. I had sold 90% of my position at $175 and the rest at $130. Today, I picked up a starter .69% position at $83.33. It might have lost its innovation for now, but it is the same tech and could do everything $NTLA can.

$ARK has been loading up on $NTLA which makes me want to avoid that like the plague as its just over priced and over hyped. I can take the bet on $CRSP for a fraction of that value. They will have a strong SCD program. I have low expectations for anything else.

I am betting they will get shift gears once they have SCD commercial and get on the ball with building their next great thing. Personally, I think they should scarf up $IPSC on the cheap for their cell therapies. Or at least do a license deal.

Read 4 tweets

Biotech2k

@Biotech2k1

19 Nov

Looking at my iPSC companies:

I heard Scott Wolchko say he thought that iPSC was the cell therapy manufacturing platform of the future. I completely agree with him. All cell therapies will move into this platform. These are my leaders in the space.

I have:

$FATE 1.38%
$SANA 2.07%
$CRBU 2.76%
$IPSC 2.76%

This theme makes up 8.96% of my portfolio.

$FATE is the clear leader and pioneer in iPSC cell therapies. Their recent R&D day revealed several new edits that continue to lead the science. They have multiple programs ongoing across all blood cancers with NK cells. They will be advancing to solid tumors.

Read 8 tweets

Biotech2k

@Biotech2k1

19 Nov

The Diabetes royal rumble.

There are 2 companies working on diabetes that are using different approaches. They are $CRSP and $SANA. Personally, I think $CRSP gets all the hype, but $SANA has be better science approach. Let us look at them here.

$CRSP has a program where they engineer islet cells to produce insulin and put them into a mechanical package from Veryacyte. This is implanted into the patient to act as a fake pancreas and release insulin.

$SANA is using induced pluripotent stem cells to grow islet cells that are completely immune masked. They replace the MHC I with HLA-E which blocks killing from T can NK cells. They implant these cell right into the pancreas where they work like normal healthy islet cells.

Read 4 tweets

Biotech2k

@Biotech2k1

19 Nov

Looking at my Targeted Protein Degrader Companies:

This is a fairly new space for me. I get that its still in early stages. I know many of the E3 ligase targets have been accidently discovered so far.

I think this space is just getting started. So much research is coming into this space for the science. There is bound to be big breakthroughs that will lead to new developments. I think this space will eventually replace the RNAi space.

It offers far more flexibility across all tissues without the worry over delivery. It offers a very clean safety profile.

Read 10 tweets

Biotech2k

@Biotech2k1

19 Nov

Looking at my Onco-Pathway Companies:

This is one of my oldest investment themes. Its been the most profitable, yet most frustrating as every time I get great companies they get bought up on me and I have to start over. That why I have 5 now.

Here is where I stand.

$BPMC 3.34%
$TPTX 5.51%
$MRTX 3.34%
$RVMD 2.76%
$ERAS 2.76%

This theme makes up 17.71% of my portfolio

$BPMC is my oldest and longest held core position. They have amazing management and a very strong pipeline that keeps on coming up with new ideas. My worst complaint is it never crashes for me to add to it anymore. Once in a while I get lucky to add some.

Read 9 tweets

Support us! We are indie developers!

This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Thank you for your support!

Share this page!

Biotech2k

Try unrolling a thread yourself!

More from @Biotech2k1

Biotech2k

Biotech2k

Biotech2k

Biotech2k

Biotech2k

Biotech2k

Did Thread Reader help you today?

Like this author's thread?